NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.00 +0.19 (+1.13 %)
(As of 09/25/2018 04:00 PM ET)
Previous Close$16.81
Today's Range$16.98 - $17.28
52-Week Range$12.01 - $19.36
Volume37,052 shs
Average Volume15,214 shs
Market Capitalization$513.24 million
P/E Ratio-11.36
Dividend YieldN/A
BetaN/A
ZEALAND PHARMA/S logoZealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.82
Quick Ratio7.82

Price-To-Earnings

Trailing P/E Ratio-11.36
Forward P/E Ratio-7.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.23 million
Price / Sales24.62
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book6.51

Profitability

EPS (Most Recent Fiscal Year)($1.48)
Net Income$-41,350,000.00
Net Margins-483.00%
Return on Equity-78.33%
Return on Assets-55.51%

Miscellaneous

Employees137
Outstanding Shares30,750,000
Market Cap$513.24 million

ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions

What is ZEALAND PHARMA/S's stock symbol?

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

When is ZEALAND PHARMA/S's next earnings date?

ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for ZEALAND PHARMA/S.

What price target have analysts set for ZEAL?

3 equities research analysts have issued twelve-month price targets for ZEALAND PHARMA/S's stock. Their predictions range from $29.00 to $29.00. On average, they expect ZEALAND PHARMA/S's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 70.6% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.

What is the consensus analysts' recommendation for ZEALAND PHARMA/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.

What are Wall Street analysts saying about ZEALAND PHARMA/S stock?

Here are some recent quotes from research analysts about ZEALAND PHARMA/S stock:
  • 1. Needham & Company LLC analysts commented, "Zealand mgmt hosted a conference call today to discuss the sale of its lixisenatide revenue stream to $205M cash. All royalties and nearly all milestone payments from Sanofi will now be diverted to Royalty Pharma. Zealand retained its right to receive a milestone payment of $10-15M from Sanofi in 2020. Net proceeds to Zealand will be approximately $150M after factoring for redemption of $24.7M royalty bond and a 13.5% payment to Alkermes. Considering our modest sales projections for lixisenatide products, we believe the transaction is priced fairly. Zealand ended 2Q18 w/ $73.1M cash. Near-term milestones include results from dasiglucagon Phase 3 trial in Acute Severe Hypoglycemia as well as Phase 3 trial initiations for glepaglutide in and dasiglucagon in Congenital Hyperinsulinism." (9/7/2018)
  • 2. According to Zacks Investment Research, "Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. " (3/15/2018)

Who are some of ZEALAND PHARMA/S's key competitors?

Who are ZEALAND PHARMA/S's key executives?

ZEALAND PHARMA/S's management team includes the folowing people:
  • Ms. Britt Meelby Jensen, CEO & Pres (Age 45)
  • Mr. Mats Peter Blom M.B.A., MBA, Exec. VP & CFO (Age 53)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 65)
  • Mr. Ivan Møller, Sr. VP of Technical Devel. & Operations
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 53)

When did ZEALAND PHARMA/S IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Who are ZEALAND PHARMA/S's major shareholders?

ZEALAND PHARMA/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.52%).

Which institutional investors are selling ZEALAND PHARMA/S stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC.

How do I buy shares of ZEALAND PHARMA/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZEALAND PHARMA/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $17.00.

How big of a company is ZEALAND PHARMA/S?

ZEALAND PHARMA/S has a market capitalization of $513.24 million and generates $21.23 million in revenue each year. The company earns $-41,350,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. ZEALAND PHARMA/S employs 137 workers across the globe.

What is ZEALAND PHARMA/S's official website?

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com.

How can I contact ZEALAND PHARMA/S?

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel